company background image
AXGN logo

AxoGen NasdaqCM:AXGN Stock Report

Last Price

US$7.77

Market Cap

US$335.7m

7D

0.4%

1Y

-14.7%

Updated

27 Mar, 2024

Data

Company Financials +

AXGN Stock Overview

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide.

AXGN fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance0/6
Financial Health4/6
Dividends0/6

AxoGen, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for AxoGen
Historical stock prices
Current Share PriceUS$7.77
52 Week HighUS$10.83
52 Week LowUS$3.45
Beta1.07
1 Month Change-25.65%
3 Month Change12.94%
1 Year Change-14.71%
3 Year Change-61.65%
5 Year Change-62.81%
Change since IPO186.72%

Recent News & Updates

Positive Sentiment Still Eludes AxoGen, Inc. (NASDAQ:AXGN) Following 26% Share Price Slump

Mar 28
Positive Sentiment Still Eludes AxoGen, Inc. (NASDAQ:AXGN) Following 26% Share Price Slump

Recent updates

Positive Sentiment Still Eludes AxoGen, Inc. (NASDAQ:AXGN) Following 26% Share Price Slump

Mar 28
Positive Sentiment Still Eludes AxoGen, Inc. (NASDAQ:AXGN) Following 26% Share Price Slump

Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 33% Share Price Boost

Jan 26
Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 33% Share Price Boost

We Think AxoGen (NASDAQ:AXGN) Has A Fair Chunk Of Debt

Sep 10
We Think AxoGen (NASDAQ:AXGN) Has A Fair Chunk Of Debt

Market Cool On AxoGen, Inc.'s (NASDAQ:AXGN) Revenues

Aug 09
Market Cool On AxoGen, Inc.'s (NASDAQ:AXGN) Revenues

AxoGen (NASDAQ:AXGN) Has Debt But No Earnings; Should You Worry?

Jan 13
AxoGen (NASDAQ:AXGN) Has Debt But No Earnings; Should You Worry?

Is AxoGen (NASDAQ:AXGN) A Risky Investment?

Sep 10
Is AxoGen (NASDAQ:AXGN) A Risky Investment?

AxoGen: Investors Are Positioned Long Leading Into Q2 FY22 Earnings

Aug 02

Axogen estimates Q2 revenue above consensus, reaffirms guidance

Jul 18

Health Check: How Prudently Does AxoGen (NASDAQ:AXGN) Use Debt?

May 04
Health Check: How Prudently Does AxoGen (NASDAQ:AXGN) Use Debt?

Axogen Needs RECON More Than Ever To Recharge The Bull Case

Mar 08

Is AxoGen (NASDAQ:AXGN) Using Debt Sensibly?

Dec 15
Is AxoGen (NASDAQ:AXGN) Using Debt Sensibly?

Axogen: Renewed Covid-19 Worries Hitting, But The Growth Story Is Very Appealing

Aug 25

Is AxoGen (NASDAQ:AXGN) Using Debt In A Risky Way?

Aug 07
Is AxoGen (NASDAQ:AXGN) Using Debt In A Risky Way?

Shareholder Returns

AXGNUS Medical EquipmentUS Market
7D0.4%2.2%0.4%
1Y-14.7%13.3%28.8%

Return vs Industry: AXGN underperformed the US Medical Equipment industry which returned 12% over the past year.

Return vs Market: AXGN underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is AXGN's price volatile compared to industry and market?
AXGN volatility
AXGN Average Weekly Movement10.2%
Medical Equipment Industry Average Movement7.7%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: AXGN's share price has been volatile over the past 3 months.

Volatility Over Time: AXGN's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a427Karen Zaderejhttps://www.axogeninc.com

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin.

AxoGen, Inc. Fundamentals Summary

How do AxoGen's earnings and revenue compare to its market cap?
AXGN fundamental statistics
Market capUS$335.71m
Earnings (TTM)-US$21.72m
Revenue (TTM)US$159.01m

2.1x

P/S Ratio

-15.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AXGN income statement (TTM)
RevenueUS$159.01m
Cost of RevenueUS$31.14m
Gross ProfitUS$127.87m
Other ExpensesUS$149.59m
Earnings-US$21.72m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.50
Gross Margin80.42%
Net Profit Margin-13.66%
Debt/Equity Ratio51.8%

How did AXGN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.